Garfield Alastair
Chief Scientific Officer at RYTM
- Sold, on record
- $998k
- Dollars the filings state
- Form 4 sales
- 2
- Latest Aug 13, 2026
- Form 144 notices
- 1
- Proposed sales
- Quarters with a sale
- 2 of the last 8
- 2 days with a sale in that time
- Companies
- 1
- Filed as an executive or holder
Companies
- RYTMRHYTHM PHARMACEUTICALS, INC.Chief Scientific Officer
Sales by reason
2
Routine
0
Plan not stated
0
No plan
0
Unusual
Form 4 sales per month, every sale on record.
Timeline
- Aug 13, 2026Routine
Sold 77.2% of their holdings
$913k7,763 shares at $117.57
- Aug 13, 2026Notice
Filed a notice to sell 7,763 shares
$913k7,763 shares
- Jul 2, 2025Routine
Sold 29.7% of their holdings
$85k1,319 shares at $64.81
3 of 3
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 17, 2026 | RYTM | Chief Scientific Officer | Sold | 7,763 | $117.57 | $913k | 2,295 | SEC |
| Jul 1, 2026 | Jul 2, 2026 | RYTM | Chief Scientific Officer | Exercised or settledRestricted Stock Units | 4,445 | 8,888 | SEC | ||
| Jul 1, 2026 | Jul 2, 2026 | RYTM | Chief Scientific Officer | Exercised options | 4,445 | 12,208 | SEC | ||
| Jul 1, 2026 | Jul 2, 2026 | RYTM | Chief Scientific Officer | Withheld for tax | 2,150 | $110.41 | $237k | 10,058 | SEC |
| Feb 11, 2026 | Feb 13, 2026 | RYTM | Chief Scientific Officer | AwardedRestricted Stock Units | 41,650 | 25,000 | SEC | ||
| Feb 1, 2026 | Feb 3, 2026 | RYTM | Chief Scientific Officer | Exercised or settledRestricted Stock Units | 6,663 | 19,987 | SEC | ||
| Feb 1, 2026 | Feb 3, 2026 | RYTM | Chief Scientific Officer | Exercised options | 6,663 | 9,789 | SEC | ||
| Feb 1, 2026 | Feb 3, 2026 | RYTM | Chief Scientific Officer | Withheld for tax | 2,026 | $108.99 | $221k | 7,763 | SEC |
| Jul 2, 2025 | Jul 3, 2025 | RYTM | Chief Scientific Officer | Sold | 1,319 | $64.81 | $85k | 3,126 | SEC |
| Jul 1, 2025 | Jul 3, 2025 | RYTM | Chief Scientific Officer | Exercised or settledRestricted Stock Units | 4,445 | 13,333 | SEC | ||
| Jul 1, 2025 | Jul 3, 2025 | RYTM | Chief Scientific Officer | Exercised options | 4,445 | 4,445 | SEC | ||
| Feb 14, 2025 | Feb 19, 2025 | RYTM | Chief Scientific Officer | AwardedRestricted Stock Units | 66,650 | 40,000 | SEC | ||
| Jul 8, 2024 | Jul 10, 2024 | RYTM | Chief Scientific Officer | AwardedStock Option (right to buy) | 71,111 | 17,778 | SEC |
Sales and notices (3)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 17, 2026 | RYTM | Chief Scientific Officer | Form 4 sale | 7,763 | $913k | 77.2% | Routine | SEC |
| Aug 13, 2026 | Aug 13, 2026 | RYTM | Chief Scientific Officer | Form 144 notice | 7,763 | $913k | Notice | SEC | |
| Jul 2, 2025 | Jul 3, 2025 | RYTM | Chief Scientific Officer | Form 4 sale | 1,319 | $85k | 29.7% | Routine | SEC |